Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)).

With an annual R&D expenditure of around euro 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of euro 7.1 billion in 2007, a history that began in 1668, and a future shaped by 31,946 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.net or http://www.merck.de


'/>"/>
SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...vehicles may reduce future disease burden, researc...News) -- Encouraging city dwellers to walk and bic...r public health benefits than increased used of lo..., The study compared the projected health effec...narios for London, England, and Delhi, India: bus...
(Date:11/27/2009)...h™ announced today that Spectrum Health (Gra...terprise orthopedic templating solution and its Tr... (PRWEB) November 27, 2009 -- Voyant Hea...rand Rapids, Michigan) has licensed its TraumaCad ...TraumaCad Extend workflow solution, to allow its o...
(Date:11/27/2009)...teractive anatomy education apps from Modality and...ciences learning opportunities for iPhone and iPod...s) November 27, 2009 -- Modality, Inc. and Lippi...Wolters Kluwer Health, today announced the availab...pp Store. Clemente’s Anatomy, Rohen’s ...
(Date:11/26/2009)...Americans living with diabetes will nearly double,...ion in 2034. Over the same period, spending on dia... to $336 billion, even with no increase in the pre...rsity of Chicago report in the December issue of ...tes covered by Medicare will rise from 8.2 million...
(Date:11/26/2009)...otional rollercoaster, study finds , , T...ear factor meets the jubilant sports fan. , A n...ose who root for the winning team -- enjoy the gre...ch and victory was in doubt, producing feelings of...anksgiving weekend as you,re glued to the TV set, ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...e-FirstCall/ - The Westaim Corporation,announced t...l western,Canadian construction services companies...posed reorganization agreement dated on,October 3,...hin 14 days of the mailing of the information circ...
... combination that included folic acid and vitamin ...l risk of cancer, including breast cancer, among w...ding to a study in the November 5 issue of JAMA ....fortification of the food supply with folic acid (...
...VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: VI...ference call on Thursday, November 6, 2008 to,disc...e call will begin at 8:30 a.m. Eastern Time., To ... start of the call. When prompted for a pass code,...
...the possibility of,a failed ceasefire and renewed ...us humanitarian situation in the Democratic Republ...carrying out urgently needed,distributions of ther...fighting reignites," said Pierre Willems, Internat...
...n insulin pump to manage diabetes is more convenie...jections. That much, physicians already know. , ...d their primary caregivers is an important questio... lives," says Dr. Max Stachura, director of the Me...
...articipation in Upcoming Investor Conferences in ...O, Nov. 4 Orexigen(R) Therapeutics,Inc. (Nasdaq: ...e treatment,of obesity and other central nervous s...uarter 2008 financial results,as well as upcoming ...
Other Medicine News:Health News:Folic acid, B vitamins do not appear to affect cancer risk 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis 2Health News:Impact of insulin pump under study 2Health News:Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008 2
(Date:11/27/2009)... ACUO TECHNOLOGIES, developers of h... data migration tools and services, is pleased to ...rk Office has approved a patent application for an...work." Acuo Technologies is pleased to add the U.S.... In general, the granted patent application broad...
(Date:11/25/2009)...5 American Scientific Re...s pleased to announce that they have opened a regi... Shanghai, China. ,, ASR has been able to secur...y for the development and production of current an...nd adults to be distributed and sold globally. Cu...
(Date:11/25/2009)... ERT (Nasdaq: ERES ), a...ompany,s President and CEO, and Keith Schneck, the...cheduled to present at the 21st Annual Piper Jaffr...er 1, 2009 in New York City, New York. ,, Inter...ing the Company,s corporate website at http://www...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2American Scientific Resources Inc. Opens Shanghai Location 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 1ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 2ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 3SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 1SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 2Shared Bed May Raise SIDS Risk 59436 1Shared Bed May Raise SIDS Risk 59436 2
...epatitis C and LymphoStat-B(R) for lupus on track ... -,- ABthrax(TM) for inhalation anthrax on track t...hened with investments in oncology portfolio and n... - GSK to advance darapladib to Phase 3 for ath...ome Sciences,Inc. (Nasdaq: HGSI ) today will repo...
... on Updated Results Showing a 20% Reduction in the...t of Disease Free Survival at Five Years, ...EWATER, N.J., May 28 Sanofi-aventis U.S.,announce... (FDA) approved,the supplemental new drug applicat...alysis from the MOSAIC trial in the Eloxatin(R) (o...
Other Medicine Technology:Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 2New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 3New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 4
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: